Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melanie Thompson

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2017
Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected AdultsJoel E Gallant, Melanie Thompson, Edwin DeJesus, et al.
AIDS (London, England)|July 30, 2005
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulationJulian Falutz, Soraya Allas, Donald Kotler, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjectsJacob Lalezari, Joseph Gathe, Cynthia Brinson, et al.
Annals of Internal Medicine|May 26, 2025
Statin Therapy as Primary Prevention for Persons With HIV: A Synopsis of Recommendations From the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines PanelCraig Beavers, Alice K Pau, David Glidden, et al.
Clinical Immunology (Orlando, Fla.)|October 6, 2007
Immunophenotypic alterations in acute and early HIV infectionLena Al-Harthi, Sam MaWhinney, Elizabeth Connick, et al.
Journal of the International AIDS Society|November 14, 2014
HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysisCynthia Brinson, Jacob Lalezari, Latiff H Gulam, et al.
Open Forum Infectious Diseases|July 17, 2025
Efficacy and Safety of Doravirine-based Regimens by Sex and Race: Long-term Results From Three Phase 3 Clinical TrialsSharon L Walmsley, Princy N Kumar, Chloe Orkin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 24, 2026
Clarification to HIVMA/IDSA HIV Primary Care Guidance Immunization RecommendationsMichael Horberg, Melanie Thompson, Allison Agwu, et al.
AIDS (London, England)|September 2, 2005
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adultsJacob Lalezari, Melanie Thompson, Priny Kumar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 11, 2024
Primary Care Guidance for Providers of Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of AmericaMichael Horberg, Melanie Thompson, Allison Agwu, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2017
Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected AdultsJoel E Gallant, Melanie Thompson, Edwin DeJesus, et al.
AIDS (London, England)|July 30, 2005
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulationJulian Falutz, Soraya Allas, Donald Kotler, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjectsJacob Lalezari, Joseph Gathe, Cynthia Brinson, et al.
Annals of Internal Medicine|May 26, 2025
Statin Therapy as Primary Prevention for Persons With HIV: A Synopsis of Recommendations From the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines PanelCraig Beavers, Alice K Pau, David Glidden, et al.
Clinical Immunology (Orlando, Fla.)|October 6, 2007
Immunophenotypic alterations in acute and early HIV infectionLena Al-Harthi, Sam MaWhinney, Elizabeth Connick, et al.
Journal of the International AIDS Society|November 14, 2014
HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysisCynthia Brinson, Jacob Lalezari, Latiff H Gulam, et al.
Open Forum Infectious Diseases|July 17, 2025
Efficacy and Safety of Doravirine-based Regimens by Sex and Race: Long-term Results From Three Phase 3 Clinical TrialsSharon L Walmsley, Princy N Kumar, Chloe Orkin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 24, 2026
Clarification to HIVMA/IDSA HIV Primary Care Guidance Immunization RecommendationsMichael Horberg, Melanie Thompson, Allison Agwu, et al.
AIDS (London, England)|September 2, 2005
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adultsJacob Lalezari, Melanie Thompson, Priny Kumar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 11, 2024
Primary Care Guidance for Providers of Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of AmericaMichael Horberg, Melanie Thompson, Allison Agwu, et al.
Pageof 6